Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. All cancer patients treated with anthracyclines~2. Informed consent must be obtained from the patient~3. Patients suspected to have been exposed to extravasation (leakage) of anthracycline, defined as:~   1. A primary assessment by the physician on duty, which would activate the standard departmental procedure for treatment of anthracycline extravasation.~  2. The presence of at least one of the following symptoms: pain, swelling or redness at the site where the anthracycline leakage is suspected to have occurred.~4. Suspicion of anthracycline extravasation from a central venous access device~5. The Topotect® infusion must be started \< 6 hours after the accident~6. 18 years of age or older~7. Performance status (PS) \< 2~Exclusion Criteria:~1. Known allergy towards dexrazoxane~2. Reasonable suspicion of extravasation by other compounds than anthracyclines through the same intravenous access, e.g. vincristine, mitomycin, and vinorelbine, all of which may cause ulceration~3. AST (aspartate aminotransferase) or ALT (alanine aminotransferase), bilirubin, LDH (lactate dehydrogenase), alkaline phosphatase \>3 x upper normal value~4. Neutrophils CTC (common toxicity criteria) ≥ grade 2. (neutrophils 1.5 x 109/L, ≥1,500/mm3)~5. Platelets CTC ≥ grade 2. (platelets ≥75.0 x 109/L, \<75,000/mm3).~6. Topical use of DMSO (dimethylsulfoxide) at the area of the accident~7. Administration of dexrazoxane within the last 3 weeks~8. Pregnant or nursing women~9. Women of childbearing age and potential, who do not use an efficient contraceptive (e.g. the Pill or a diaphragm plus a spermicide) for at least 3 months prior to the start of trial medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).